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To estimate the prevalence of congenital toxoplasmo-
sis, Chagas disease, cytomegalovirus, and rubella, blood
samples on dried blood spot (DBS) from neonates (day
3–20 of life) were screened for immunoglobulin (Ig) M
against Toxoplasma gondii, cytomegalovirus, rubella virus,
and IgG against Trypanosoma cruzi by methods used for
serum and adapted for use with DBS. Positive samples
were further analyzed for IgM and IgG in serum from
neonates and mothers. DBS samples from 364,130
neonates were tested for Toxoplasma gondii–specific IgM,
and 15,873 neonates were also tested for IgM against
cytomegalovirus and rubella virus and for Trypanosoma
cruzi–specific IgG. A total of 195 were diagnosed with con-
genital toxoplasmosis, 16 with cytomegalovirus, and 11
with congenital rubella. One newborn had a confirmed
result for Chagas disease, and 21 mothers had positive
serum antibodies. These results suggest that infectious dis-
eases should be considered for future inclusion in pro-
grams for newborn screening of metabolic diseases in
disease-endemic areas. 
T
oxoplasmosis infection during pregnancy can cause
congenital infection and manifestations, such as men-
tal retardation and blindness (1). Hydrocephalus, intracra-
nial calcification, and retinochoroiditis are the most
common manifestations of tissue damage from congenital
toxoplasmosis. However, the effect of prenatal treatment
on these outcomes is unclear (2), and the best method for
preventing and controlling congenital toxoplasmosis is
controversial. A neonatal screening program based on
detecting immunoglobulin (Ig) M antibodies against
Toxoplasma gondii alone would identify 70%–80% of con-
genital toxoplasmosis cases (3). Moreover, prenatal
screening has indicated neither the natural history of toxo-
plasmosis nor the efficacy of antiparasite treatment during
pregnancy (4). A study by Guerina et al. (5) showed a
prevalence of congenital toxoplasmosis of 1 per 10,000
live births in the United States, where 85% of women of
childbearing age are susceptible to acute infection with T.
gondii (6).
Congenital Chagas disease has been reported, mostly in
Latin America (7), where approximately 20 million per-
sons are affected; 90 million others are at risk of being
infected by the parasite (8). The high prevalence of the dis-
ease has been demonstrated in several Latin American
countries (8–10). The evolution of the congenital and reac-
tive forms of the disease has yet to be determined (11). The
vertical transmission of Trypanosoma cruzi cannot be pre-
vented, but early detection and treatment of congenital
infection achieve cure rates close to 100% (12–14).
Persons infected by T. cruzi can be successfully treated
with nifurtimox or benzonidazole (12,14).
Cytomegalovirus is the most common congenital virus
infection in the world. Both primary and recurrent infec-
tion can result in fetal infection. The birth prevalence of
congenital cytomegalovirus infection varies from 0.3% to
2.4%, and at least 90% of congenitally infected infants
have no clinical signs (15). The disease causes illnesses
ranging from no clinical signs to prematurity, encephalitis,
deafness, hematologic disorders, and death (16).
Congenital cytomegalovirus infection is described in
30,000 to 40,000 newborns each year in the United States;
approximately 9,000 of these children have permanent
neurologic sequelae (17). The death rate of symptomatic
congenital cytomegalovirus infection is approximately
30% (18). The value of vaccination against congenital
cytomegalovirus infection is not known, and screening of
newborn infants has been recommended to indicate infants
at high risk for deafness and to make early rehabilitation
possible (18). 
Rubella virus infection during early pregnancy can lead
to severe birth defects known as congenital rubella syn-
drome (19). Sequelae of rubella virus infection include three
distinct neurologic syndromes: postinfectious encephalitis
after acute infection, a range of neurologic manifestations
after congenital infection, and an extremely rare neurode-
generative disorder, progressive rubella panencephalitis,
that can follow either congenital or postnatal infection (19).
A review of the literature that identified studies about the
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tries concluded that congenital rubella syndrome is an
under-recognized public health problem and that appropri-
ate data need to be collected to estimate the cost-effective-
ness of a potential global rubella control program (20).
Material and Methods
Samples 
Blood was obtained by heel puncture and applied on fil-
ter paper Schleicher and Schuell 903 (Keene, NH, USA),
between day 3 and day 20 of life (mean day 10). The sam-
ples were collected in areas throughout Brazil and sent by
mail to Porto Alegre, South Brazil, where the tests were
performed. 
Tests in Filter Paper Dried Blood Spots (DBS)
An indirect enzymatic immunoassay for IgM
anti–Toxoplasma gondii prepared in-house (21) was used
to test the first 78,350 samples. A fluorometric capture
enzymatic immunoassay (FEIA) (Neonatal Toxoplasma
gondii, AniLabsystems, Helsinki, Finland) was used in
285,780 samples. A kit produced by Wiener Laboratory
(Rosario, Argentina) to detect IgG against Trypanosoma
cruzi in human serum was adapted. In brief, a 3.2-mm
DBS paper disk was placed in microtiter plates precoated
with T. cruzi. The serum was eluted with 200 µL of phos-
phate-buffered saline (PBS)/bovine serum albumin (BSA)
buffer on an orbital shaker set at 100 rpm for 60 min and
incubated for 14–16 h at room temperature. After washing
with PBS/BSA buffer, the protocol was followed accord-
ing to the manufacturer’s instructions with two modifica-
tions: the reactions occurred at room temperature, and the
incubation times were duplicated, except after the addition
of the color reagent. Also, two kits produced by Diesse
Diagnostica Senese (Monteriggioni, Italy) were adapted to
detect IgM against cytomegalovirus and IgM against
rubella in human serum eluted from filter paper. A3.2-mm
DBS paper disk was placed in microtiter plates precoated
with an anti-human IgM monoclonal antibody. The serum
was eluted with 150 µL of PBS/BSA buffer on an orbital
shaker set at 100 rpm for 2 h at room temperature.
Afterwards, the protocol was followed according to the
manufacturer’s instructions with the same modifications
made with the IgG Chagas test.
Controls
The cutoff for each test was obtained by testing 97
whole blood samples negative for IgM Toxoplasma gondii
antibodies, 95 whole blood samples negative for IgG
Trypanosoma cruzi antibodies, and 86 whole blood sam-
ples negative for IgM cytomegalovirus and rubella virus
antibodies. The cutoff was established as three times the
mean optical density of the negative samples. Negative,
cutoff, and positive control samples were prepared in DBS
for each test. The sensitivity of the methods was tested
with 55 positive IgM Toxoplasma gondii samples, 43 IgG
positive  Trypanosoma samples, and 40 positive IgM
cytomegalovirus and rubella samples. All samples were
over the cutoff point for a preliminary analytical sensitivi-
ty of 100%. The presumptive positive samples were con-
firmed in a new duplicate run. 
Confirmatory Serologic Tests
Serum tests were performed on samples from the moth-
ers and neonates. For the first 202 case-patients with pos-
sible congenital toxoplasmosis and Chagas disease, an
indirect immufluorescence test (Biolab-Meriéux
Diagnóstica, Rio de Janeiro, Brazil) was used.
Confirmatory serum tests for toxoplasmosis, cytomegalo-
virus, and rubella (IgM and IgG) were run by microparti-
cle enzyme immunoassay (MEIA) in the Axsym (Abbott
Laboratories, Chicago, IL). The FEIAmethod was used for
serum tests and run in parallel with the Axsym, which
showed good agreement.
Clinical Examination of Infected Infants
Patients suspected to have congenital toxoplasmosis
and cytomegalovirus were given a skull ultrasound,
tomography, or x-ray and ophthalmoscopic and audiologic
exams. Patients suspected to have congenital Chagas dis-
ease and their mothers were evaluated for cardiac and
esophageal malformations. Patients suspected to have con-
genital rubella were evaluated for hearing loss and eye
lesions. When the samples were above or maximally 20%
below the cutoff value, serum samples from the infant and
the mother were requested. All clinical and follow-up
information was obtained by contacting the pediatricians
or, in rare cases, the families.
A neonate was followed and classified as infected by
meeting one of the following criteria: antigen-specific IgM
and IgG in the neonate and in the mother, antigen-specific
IgM in the neonate only, antigen-specific IgM in the moth-
er only, or increased amount of antigen-specific IgG in the
neonate. An increase in the neonate’s IgG antibodies
excluded maternal origin. 
Results
Congenital Toxoplasmosis
We analyzed 364,130 DBS samples for IgM against
Toxoplasma gondii, and 699 samples were positive; all
were recalled for serum confirmation. Serum samples
from 594 neonates and 576 mothers were received, and of
these, 202 suspected cases were tested by indirect
immunofluorescence (IIF) (17 diagnosed with congenital
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(178 were diagnosed with congenital toxoplasmosis). A
total of 195 neonates (1 in 1,867) were confirmed to have
congenital toxoplasmosis. The laboratory findings are
presented in Table 1, and the clinical findings are summa-
rized in Table 2. The false-positive percentage was 0.16%.
All patients with confirmed diagnoses were given sulpha-
diazine, pyrimethamine, and folinic acid.
Of the 195 patients with congenital toxoplasmosis, 138
(70.7%) were asymptomatic until 7 years of age. One IgM-
positive asymptomatic infant also had HIV, and six patients
with sequelae received late treatment (6–14 months after
diagnosis) and could be asymptomatic if treated early. The
follow-up was 1–84 months (mean 30 months).
Congenital Chagas Disease
We analyzed 15,873 DBS samples for Chagas disease
and had 36 positive results. Serum samples from 31
neonates and 30 mothers were received for confirmatory
tests. Results are shown in Table 1. The prevalence of spe-
cific Trypanosoma cruzi–specific IgG was estimated in 1
in 756 mothers (false-positive rate of 0.08%). All mothers
and neonates had x-rays and echocardiographys. One
mother (age 41) had an expanded heart and had a brother
with Chagas disease. All others were asymptomatic and
are under clinical observation. The antibodies observed in
the neonates disappeared in time. The follow-up for posi-
tive children was 1–24 months (mean 15 months). 
Congenital Cytomegalovirus
A total of 15,873 DBS samples for IgM against
cytomegalovirus were analyzed, and 39 were positive.
Thirty-two serum samples from neonates and 30 from
mothers were received for confirmatory testing, and 16
cases were confirmed (Table 1). In 8 case-patients, the IgG
levels decreased in the neonates, and in 15 case-patients,
IgG in the neonates’serum only was interpreted by the cli-
nicians as being of maternal origin. Likewise, in one case,
antigen-specific IgM was detected only in the mother’s
serum and antigen-specific IgG only in the neonate’s
serum. This neonate was not followed. The prevalence of
cytomegalovirus was estimated at 1 in 992 live births, and
the false-positive was 0.11%. The follow-up of the infect-
ed patients showed that 11 were asymptomatic until 2
years of age, including a premature baby (36 weeks’gesta-
tion). Laboratory results and clinical findings are present-
ed in Tables 1 and 3. The follow-up was 1–24 months
(mean 15 months). 
Congenital Rubella
A total of 15,873 DBS samples for IgM against rubella
virus were analyzed, and positive results were obtained in
67. Serum samples from 55 neonates and 52 mothers were
received, and 16 were positive. Four mothers and one
neonate were vaccinated against rubella and were exclud-
ed from the sample. The prevalence estimated was at 1 in
1,443, and the false-positive rate was 0.30%. Of 49
neonates and mothers without detectable IgM, 30 were fol-
lowed until the specific IgG levels decreased. In 19 cases,
the infant’s IgG levels were interpreted by the pediatrician
as being of maternal origin and were not followed. From
these cases, three mothers received rubella vaccine before
pregnancy. The follow-up of the 11 positive cases is shown
in Table 4. The follow-up was 1–24 months (mean 15
months). 
Discussion
In screening for congenital toxoplasmosis, 195
neonates had diagnosis confirmed, and 105 (53.8%) had
specific IgM. The diagnosis of 41 cases (21%) was only
possible by monitoring the specific IgG levels in the
infants; 49 (25%) cases were followed because of IgM in
the mother’s serum samples. Some mistakes may have
occurred in the clinical evaluation of neonates in whom
IgM were not detected in serum. A prospective study
showed that a serologically transient toxoplasmosis
occurred in 15% of the cases of unknown pathophysiolo-
gy, leading to a risk of misdiagnosis and inadequate sur-
veillance (22). The clinical decision not to monitor IgG
levels in 123 patients for whom IgM was detected only in
the mother’s serum suggests that the concept still prevails:
in the absence of IgM in the neonate, the IgG is from
maternal origin. Several cases might have been misdiag-
nosed in these cases. In some cases, the beginning of treat-
ment was delayed because of the following: 1)
unwillingness of the clinician to treat asymptomatic
infants because of the toxicity of the drugs; 2) time elapsed
between birth, screening, confirmatory tests, and clinical
examinations; and 3) the decision of the family to consult
another physician. 
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Table 1. Serum results in the confirmatory tests 
Disease  IgM
a in mother and neonate  IgM in neonate  IgM in mother  Increase of IgG in neonate 
Congenital toxoplasmosis  84  21  49  41 
Chagas disease  1
b  1  1  1
b 
Cytomegalovirus infection  6  9 (2 adopted)  1
b  1
b 
Congenital rubella  8 (4 mothers vaccinated)  9 (2 adopted)  2
b  1
b 
aIg, immunoglobulin.
 
bSame neonate. Congenital toxoplasmosis is routine in prenatal studies
in France, and the efficacy of this program is difficult to
estimate, even considering the benefits (23). Moreover,
prenatal programs have the risk of invasive methods and,
according to Lebech (3), testing for specific IgM shows a
better cost-benefit ratio if included in newborn-screening
programs. 
In 41 confirmatory serum tests for Chagas disease on
samples from 21 neonates and 20 mothers, IgM antibodies
were found in one neonate. He was treated and remains
asymptomatic. IgG levels decreased in all asymptomatic
neonates. One mother was identified with cardiac enlarge-
ment, and all the others received clinical counseling. In the
population studied, most of the samples came from urban
areas, and the incidence of mothers with specific antibod-
ies (1 in 756) suggests that the seroprevalence can be high-
er in rural and disease-endemic areas (9,11,12). Because
testing to detect IgM against Trypanosoma cruzi is not
available, neonatal screening could detect asymptomatic
mothers.
IgM against cytomegalovirus was detected in 87.5% of
the patients diagnosed with congenital cytomegalovirus;
68.8% were asymptomatic. In 15 neonates, having only
IgG antibodies in the serum was interpreted as being of
maternal origin by the clinicians. The lack of information
about the synthesis of specific antibodies against
cytomegalovirus could be justified for the same reasons
described previously for congenital toxoplasmosis (22). In
a 16-year study, 388 children with congenital
cytomegalovirus were evaluated for neurosensorial hear-
ing loss (24). Ahearing deficit was observed in 5.2% of the
cases at birth and 15.4% in children >6 years of age, and
neonatal screening for cytomegalovirus infection was sug-
gested (23). Symptomatic cytomegalovirus can occur after
maternal recurrent infection, but the incidence of these
cases is still not established (16). Seropositive women
reinfected by a different strain of cytomegalovirus can
transmit the infection to the fetus and deliver a sympto-
matic child (25,26). In this work, the incidence of congen-
ital infection by the cytomegalovirus was estimated to be 1
in 992. A successful treatment with the combined use of
ganciclovir and anti-cytomegalovirus immunoglogulin
was reported (27).
Because of the mass vaccination to rubella, the high
incidence of positive tests was unexpected (1 in 1,443,
excluding the positive tests in vaccinated mothers). The
results confirmed the findings of Cutts and Vynnycky (20)
that the disease is under-recognized in developing coun-
tries. As observed with congenital toxoplasmosis and
cytomegalovirus, 38.7% of neonates showed only IgG
antibodies in the confirmatory tests. No further investiga-
tion was made because the clinicians presumed at follow-
up that IgG was of maternal origin. Also, rubella
vaccination of young women does not seem to be enough
to prevent the transmission of the virus in a future pregnan-
cy (28). However, prenatal care and mass vaccination
seem to be the better choices to prevent new cases of con-
genital rubella. The purpose of neonatal screening would
be to identify congenitally asymptomatic, infected
neonates at birth. In Brazil (170 million persons and
approximately 2,400,000 newborns/year), the prevalence
of infectious diseases is higher than phenylketonuria (1 in
13,000) and congenital hypothyroidism (1 in 3,500).
Congenital toxoplasmosis, with well-defined treatment
protocols and a high prevalence, deserves special attention
from health authorities, and its inclusion in screening pro-
grams should be considered. The follow-up of children
until 7 years of age showed that most patients treated were
asymptomatic or that the sequelae observed at the time of
diagnosis had not progressed. By using the existing pro-
grams of newborn screening in the country, the inclusion
of congenital toxoplasmosis, cytomegalovirus, and Chagas
disease in disease-endemic areas would increase the cost
RESEARCH
1072 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 6, June 2004
Table 2. Symptoms and findings in patients with congenital 
toxoplasmosis 
n 
Complementary 
examination  Clinical findings 
25  Retinal scar or 
retinochoroiditis 
2 blind, 1 with myopia  
14  Intracranial 
calcifications 
1 with cognitive deficiency, 4 with 
splenomegaly or hepatosplenomegaly 
(HSM) 
7  Retinal scar or 
retinochoroiditis 
and intracranial 
calcifications 
2 with splenomegaly or HSM, 2 with 
neuromotor retardation, 1 microcephaly, 1 
hydrocephaly and microophthalmia, 1  
died immunosuppressed 
7  Other 
symptoms 
Splenomegaly or HSM, neuromotor 
retardation, microcephaly, hydrocephaly 
and microophthalmia, 1 died 
immunosuppressed 
Table 3. Pediatric decision and symptoms presented in patients 
with congenital cytomegalovirus 
n  Decision  Symptoms 
5  No treatment  Asymptomatic, clinical follow-up 
6  Symptomatic; treated 
with ganciclovir 
Microcephaly, intracranial 
calcifications, deafness, failure to 
thrive, HSM
a (initially investigated 
for galactosemia), progressive 
muscular atrophy, sepsis, low 
weight, difficulty swallowing (died), 
thrombocytopenia, leukopenia  
aHSM, hepatosplenomegaly. 
Table 4. Symptoms and number of patients with congenital 
rubella 
Asymptomatic  Symptomatic 
6 (1 adopted)  1 congenital rubella syndrome (died) 
  2 with scars in 1 eye 
  1 with cataract and received lens implant 
  1 with cardiopathy and partial deafness of the program to approximately U.S.$1.50 per test. Also,
treating infectious diseases is cheaper, and the time of
treatment is shorter when compared to the expensive and
long-term treatment of metabolic diseases. Studies on
long-term follow-up of these children are in progress for a
better understanding of the efficacy of the treatments and
the effectiveness of mass screening. 
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